Exact Sciences Corporation EXAS | NASDAQ
After Hours
Company Overview:
5.9 Year Performance Metrics:
EXAS Dividend Payments, Yield & Share Price charts
Unlock All Reports & Research Dividend Stocks like a BOSS!
EXAS Dividend Safety: Payout & Dividend to Free Cash Flow Ratios.
Dividend payout ration is Dividend/EPS, and indicates if company can afford to pay dividends from net income that it earned in the quarter.
Since EPS can be played with using different "accounting gymnastics", a better measure of dividends safety is Dividend to Free Cash Flow (FCF) ratio.
FCF is how much cash the company has earned each quarter, after paying all expenses not related to earnings.
Lower Ratio indicates SAFER Dividend! Ratios consistently close to, or over 100% are usually unsustainable and often indicate a dividend cut might be coming soon.
EXAS Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
EXAS Dividends Info:
EXAS Dividend History: Dates, Payments & Yield list
Below is a schedule of all EXAS dividend payments, ex-dates, share price on the day of the payment as well as TTM & forward yield
| Ex-Date | Payment Date | Amount | TTM Yield | Forward Yield | Price on Ex-Date |
|---|
Get the best Dividend Stock Research Tools:
Projected Future Returns & Dividends for EXAS
Based on past 5.9-year performance, here are EXAS growth metrics:Using EXAS CAGR metrics, we can estimate, that your initial $10000 investment, over next 10 years ago, should grow with dividends being reinvested (DRIP) as follows:
Share price CAGR of -9.47%
Dividend CAGR of +0%
| EXAS | |
|---|---|
| Current Price | $59.40 |
| Start Shares | 168.35 |
| Start Value | $10,000 |
| After 10 years: | |
| Final Share Count | 168.35 |
| Dividends Payment | $0.00 |
| Annual Dividends | $0 |
| Yield on cost | 0.00% |
| Share Price | $24.26 |
| Total Dividends | $0 |
| Final Value | $4,085 |
NOTE: Above numbers are our estimate based on EXAS's Dividend and Price CAGR over past 5.9 years.
These numebrs should only be considered as "potential future returns"! These numbers assume DRIP (reinvesting dividends).
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Exact Sciences Corporation (EXAS) had its IPO on 2001-02-01, and is trader on NASDAQ stock exchange.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXAS website: https://www.exactsciences.com
